Publications by authors named "Elba Marin"

Claim this Profile
N
Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer.
Fernando Martín, Clara Alcon, Elba Marín, Paula Morales-Sánchez, Albert Manzano-Muñoz

Cell Death Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non-Small Cell Lung Cancer.
Roberto Martin-Deleon, Cristina Teixido, Carmen Mª Lucena, Daniel Martinez, Ainhoa Fontana, Elba Marin

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer.
Cristina Aguado, Cristina Teixido, Ruth Román, Roxana Reyes, Ana Giménez-Capitán, Elba Marin

Mol Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients.
Elba Marin, Roxana Reyes, Ainara Arcocha, Nuria Viñolas, Laura Mezquita

Diagnostics (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients.
Elba Marin, Cristina Teixido, Elena Carmona-Rocha, Roxana Reyes, Ainara Arcocha

Cancers (Basel)· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer.
Noemí Reguart, Elba Marin, Jordi Remon, Roxana Reyes, Cristina Teixido

Drugs· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Roxana Reyes, Clara Mayo-de-Las-Casas, Cristina Teixidó, Carlos Cabrera, Elba Marín

Clin Lung Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis